Anaplastic astrocytoma is a rare malignant brain tumor that develops from certain star-shaped brain cells known as astrocytes. Astrocytes and similar cells form tissue that surrounds and protects other nerve cells found within the brain and spinal cord. Collectively, these cells are known as glial cells and the tissue they form is known as glial tissue. Tumors that arise from glial tissue, including astrocytomas, are collectively referred to as gliomas. The symptoms of anaplastic astrocytomas vary depending upon the specific location and size of the tumor. The specific cause of this tumor is unknown. The treatment of anaplastic astrocytoma includes radiation therapy, that is used to treat an unremovable low-grade astrocytoma. Other than radiation therapy, chemotherapy is also used to treat tumors of anaplastic astrocytoma. The drug candidates of anaplastic astrocytoma pipeline include, but are not limited to Eflornithine + Lomustine, Toca 511 (vocimagene amiretrorepvec) + Toca FC (extended-release 5-fluorocytosine) and AdRTSIL-12.
Some of the companies operating in anaplastic astrocytoma therapeutics pipeline are Advantagene Inc., Amgen Inc., AngioChem Inc., and Bayer AG.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.